91 related articles for article (PubMed ID: 26684261)
21. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
22. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
[TBL] [Abstract][Full Text] [Related]
23. Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.
Vermeulen R; Saberi Hosnijeh F; Bodinier B; Portengen L; Liquet B; Garrido-Manriquez J; Lokhorst H; Bergdahl IA; Kyrtopoulos SA; Johansson AS; Georgiadis P; Melin B; Palli D; Krogh V; Panico S; Sacerdote C; Tumino R; Vineis P; Castagné R; Chadeau-Hyam M; ; Botsivali M; Chatziioannou A; Valavanis I; Kleinjans JCS; de Kok TMCM; Keun HC; Athersuch TJ; Kelly R; Lenner P; Hallmans G; Stephanou EG; Myridakis A; Kogevinas M; Fazzo L; De Santis M; Comba P; Bendinelli B; Kiviranta H; Rantakokko P; Airaksinen R; Ruokojarvi P; Gilthorpe M; Fleming S; Fleming T; Tu YK; Lundh T; Chien KL; Chen WJ; Lee WC; Kate Hsiao C; Kuo PH; Hung H; Liao SF
Int J Cancer; 2018 Sep; 143(6):1335-1347. PubMed ID: 29667176
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Ann Rheum Dis; 2006 Nov; 65(11):1484-9. PubMed ID: 16504995
[TBL] [Abstract][Full Text] [Related]
25. Plasma soluble CD30 level correlates negatively with age in children.
Chen JY; Fu LS; Chu JJ; Chen HC; Chi CS
J Microbiol Immunol Infect; 2007 Apr; 40(2):168-72. PubMed ID: 17446967
[TBL] [Abstract][Full Text] [Related]
26. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
27. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
[TBL] [Abstract][Full Text] [Related]
29. Association of serum-soluble CD26 and CD30 levels with asthma, lung function and bronchial hyper-responsiveness at school age.
Remes ST; Delezuch W; Pulkki K; Pekkanen J; Korppi M; Matinlauri IH
Acta Paediatr; 2011 Sep; 100(9):e106-11. PubMed ID: 21401715
[TBL] [Abstract][Full Text] [Related]
30. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy.
Sadeghi M; Süsal C; Daniel V; Naujokat C; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):886-90. PubMed ID: 17678471
[TBL] [Abstract][Full Text] [Related]
31. Serum and CSF soluble CD26 and CD30 concentrations in healthy pediatric surgical outpatients.
Delezuch W; Marttinen P; Kokki H; Heikkinen M; Vanamo K; Pulkki K; Matinlauri I
Tissue Antigens; 2012 Oct; 80(4):368-75. PubMed ID: 22861386
[TBL] [Abstract][Full Text] [Related]
32. Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin's lymphomas: evidence from a meta-analysis.
Huang YS; Zhou X; Yang ZF; Lv ZT
Ann Hematol; 2018 Aug; 97(8):1317-1325. PubMed ID: 29750316
[TBL] [Abstract][Full Text] [Related]
33. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.
Kato K; Chu P; Takahashi S; Hamada H; Kipps TJ
Exp Hematol; 2007 Mar; 35(3):434-42. PubMed ID: 17309824
[TBL] [Abstract][Full Text] [Related]
34. Age-dependent changes of serum soluble CD30 concentration in children.
Chrul S; Polakowska E
Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
[TBL] [Abstract][Full Text] [Related]
35. Effect of fluticasone propionate on soluble CD30 release in patients with severe allergic asthma.
Purello-D'Ambrosio F; Gangemi S; Ruello G; Marotta G; Merendino RA
J Investig Allergol Clin Immunol; 2000; 10(5):283-5. PubMed ID: 11108439
[TBL] [Abstract][Full Text] [Related]
36. Microvillous lymphomas are B-cell neoplasms that frequently express CD56.
Hammer RD; Vnencak-Jones CL; Manning SS; Glick AD; Kinney MC
Mod Pathol; 1998 Mar; 11(3):239-46. PubMed ID: 9521469
[TBL] [Abstract][Full Text] [Related]
37. In vitro soluble CD30 levels in patients with chronic stable coronary artery disease.
Mahmoudi MJ; Hedayat M; Rezaei N; Saboor-Yaraghi AA; Mahmoudi M
Iran J Allergy Asthma Immunol; 2011 Dec; 10(4):237-42. PubMed ID: 22184265
[TBL] [Abstract][Full Text] [Related]
38. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
Heshmat NM; El-Hadidi ES
Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of pre transplant T-cell activation status by soluble CD 30 determination.
Abbas K; Muzaffar R; Zafar MN; Mubarak M; Naqvi SA; Rizvi SA
J Pak Med Assoc; 2009 Apr; 59(4):212-5. PubMed ID: 19402280
[TBL] [Abstract][Full Text] [Related]
40. A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation.
Hübel K; Cremer B; Heuser E; von Strandmann EP; Hallek M; Hansen HP
Transpl Immunol; 2010 Aug; 23(4):215-9. PubMed ID: 20620210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
